Hepatitis C treatment Market - 2024-2031
Hepatitis C treatment Marketis is growing with a CAGR of 13.50% during the forecast period 2026-2035.
The Hepatitis C treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Hepatitis C treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
Both primary and secondary data sources have been used in the global Hepatitis C treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Hepatitis C treatment Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Hepatitis C treatment Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Class
- HCV Protease Inhibitors*
- Paritaprevir
- Glecaprevir
- Grazoprevir
- Others
- HCV Polymerase Inhibitors
- Ledipasvir/sofosbuvir
- Sofosbuvir
- Sovaldi
- Combination Therapy
- Ledipasvir/sofosbuvir (Harvoni)
- Elbasvir-grazoprevir (Zepatier)
- Sofosbuvir-velpatasvir (Epclusa)
- Sofosbuvir-velpatasvir-voxilaprevir (Vosevi)
- Glecaprevir-pibrentasvir (Mavyret)
- Interferon
- Interferon alfa-2b (Intron-A)
- Peginterferon alfa-2b (PEG-Intron, Sylatron)
- Ribavirin (Rebetol, Virazole, Copegus, Moderiba, Ribasphere)
- Others
- Hospital Pharmacies*
- Retail Pharmacies
- Online Pharmacies
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Hepatitis C treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Raising awareness about hepatitis C infection among people is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Stringent regulatory approvals of the products by the government are expected to hamper the growth of the market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Epidemiology Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG CLASS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. HCV Protease Inhibitors*
7.2.1. Paritaprevir
7.2.2. Glecaprevir
7.2.3. Grazoprevir
7.2.4. Others
7.2.5. Introduction
7.2.6. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. HCV Polymerase Inhibitors
7.3.1. Ledipasvir/sofosbuvir
7.3.2. Sofosbuvir
7.3.3. Sovaldi
7.3.4. Others
7.4. Combination Therapy
7.4.1. Ledipasvir/sofosbuvir (Harvoni)
7.4.2. Elbasvir-grazoprevir (Zepatier)
7.4.3. Sofosbuvir-velpatasvir (Epclusa)
7.4.4. Sofosbuvir-velpatasvir-voxilaprevir (Vosevi)
7.4.5. Glecaprevir-pibrentasvir (Mavyret)
7.4.6. Others
7.5. Interferon
7.5.1. Interferon alfa-2b (Intron-A)
7.5.2. Peginterferon alfa-2b (PEG-Intron, Sylatron)
7.5.3. Ribavirin (Rebetol, Virazole, Copegus, Moderiba, Ribasphere)
7.5.4. Others
7.6. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel Segment
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Retail Pharmacies
8.4. Online Pharmacies
8.5. Others
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. U.K.
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
10.4. List of Key Companies to Watch
11. COMPANY PROFILES
11.1. AbbVie Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Merck & Co., Inc.
11.3. Gilead Sciences, Inc.
11.4. Genentech, Inc.
11.5. Kadmon Pharmaceuticals, LLC
11.6. Cipla Ltd
11.7. Mylan Laboratories Limited
11.8. Strides Arcolab Limited(*LIST NOT EXHAUSTIVE)
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About Us and Applications
12.3. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. MARKET DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Market Snippet by Drug Class
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region
4. MARKET DYNAMICS
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Raising awareness about hepatitis C infection among people is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Stringent regulatory approvals of the products by the government are expected to hamper the growth of the market.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Epidemiology Analysis
5.2. Pipeline Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Unmet Needs
6. COVID-19 ANALYSIS
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY DRUG CLASS
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. HCV Protease Inhibitors*
7.2.1. Paritaprevir
7.2.2. Glecaprevir
7.2.3. Grazoprevir
7.2.4. Others
7.2.5. Introduction
7.2.6. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. HCV Polymerase Inhibitors
7.3.1. Ledipasvir/sofosbuvir
7.3.2. Sofosbuvir
7.3.3. Sovaldi
7.3.4. Others
7.4. Combination Therapy
7.4.1. Ledipasvir/sofosbuvir (Harvoni)
7.4.2. Elbasvir-grazoprevir (Zepatier)
7.4.3. Sofosbuvir-velpatasvir (Epclusa)
7.4.4. Sofosbuvir-velpatasvir-voxilaprevir (Vosevi)
7.4.5. Glecaprevir-pibrentasvir (Mavyret)
7.4.6. Others
7.5. Interferon
7.5.1. Interferon alfa-2b (Intron-A)
7.5.2. Peginterferon alfa-2b (PEG-Intron, Sylatron)
7.5.3. Ribavirin (Rebetol, Virazole, Copegus, Moderiba, Ribasphere)
7.5.4. Others
7.6. Others
8. BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel Segment
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Retail Pharmacies
8.4. Online Pharmacies
8.5. Others
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. U.K.
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10. COMPETITIVE LANDSCAPE
10.1. Key Developments and Strategies
10.2. Company Share Analysis
10.3. Product Benchmarking
10.4. List of Key Companies to Watch
11. COMPANY PROFILES
11.1. AbbVie Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Merck & Co., Inc.
11.3. Gilead Sciences, Inc.
11.4. Genentech, Inc.
11.5. Kadmon Pharmaceuticals, LLC
11.6. Cipla Ltd
11.7. Mylan Laboratories Limited
11.8. Strides Arcolab Limited(*LIST NOT EXHAUSTIVE)
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About Us and Applications
12.3. Contact Us
